Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted drug tame neuroendocrine tumors in everyday practice?

NCT ID NCT07780539

Disease control Sponsor: Yefeng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study looks at how well the drug surufatinib works and how safe it is for people with neuroendocrine tumors, a type of cancer that grows from hormone-producing cells. Researchers will follow about 60 patients who receive surufatinib either alone or with other treatments, as decided by their doctor. The main goal is to see how long patients live without their cancer getting worse, with additional checks on tumor shrinkage and side effects. The findings could help guide real-world treatment decisions and improve care for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
surufatinib, a targeted cancer drug, given alone or with other treatments
What this could lead to
If successful, this could provide stronger evidence that surufatinib helps control neuroendocrine tumors, potentially improving treatment options and outcomes for patients.
What could go wrong
This is a real-world study with a modest number of participants, so results may vary and not apply to everyone. Side effects are possible, and the drug may not work as well outside controlled trial settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Advanced neuroendocrine tumor

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with pathologically or cytologically confirmed neuroendocrine tumors; * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; * Life expectancy ≥ 12 weeks; * Adequate organ and bone marrow function Exclusion Criteria: * Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks; * History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ; * Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.); * Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally; * Any condition deemed by the investigator as unsuitable for study drug treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine (NE) tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine (NE) tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.